[go: up one dir, main page]

De Mey et al., 2009 - Google Patents

Endothelin-1, an endogenous irreversible agonist in search of an allosteric inhibitor

De Mey et al., 2009

View PDF
Document ID
14472339351335281138
Author
De Mey J
Compeer M
Meens M
Publication year
Publication venue
Mol Cell Pharmacol

External Links

Snippet

Abstract Endothelin-1 (ET-1), a 21 amino acid paracrine mediator and long-acting stimulus of G-protein coupled receptors (GPCRs), is implicated in cardiovascular diseases and cancers. We have recently demonstrated that the sensory-motor neurotransmitter calcitonin …
Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines

Similar Documents

Publication Publication Date Title
Grant et al. Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization
Dumont et al. BIIE0246, a potent and highly selective non‐peptide neuropeptide Y Y2 receptor antagonist
US9937165B2 (en) Pharmacological chaperones for treating obesity
Barak et al. ML314: a biased neurotensin receptor ligand for methamphetamine abuse
Pheng et al. Agonist‐and antagonist‐induced sequestration/internalization of neuropeptide Y Y1 receptors in HEK293 cells
Hay What makes a CGRP2 receptor?
Yamamoto et al. A structure–activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are δ/μ opioid receptor agonists and neurokinin 1 receptor antagonists
Chruscicka et al. Attenuation of oxytocin and serotonin 2A receptor signaling through novel heteroreceptor formation
Wehbi et al. Partially deglycosylated equine LH preferentially activates β-arrestin-dependent signaling at the follicle-stimulating hormone receptor
Kokko et al. In vitro analysis of stable, receptor-selective neurotensin [8− 13] analogues
Meens et al. Stimuli of sensory-motor nerves terminate arterial contractile effects of endothelin-1 by CGRP and dissociation of ET-1/ETA-receptor complexes
De Mey et al. Endothelin-1, an endogenous irreversible agonist in search of an allosteric inhibitor
Fioravanti et al. The ORL-1 receptor system: are there opportunities for antagonists in pain therapy?
Judd et al. Structure–activity studies on high affinity NOP‐active hexapeptides
Alexander et al. Novel fluorescently labeled PACAP and VIP highlight differences between peptide internalization and receptor pharmacology
Rihakova et al. VRQ397 (CRAVKY): a novel noncompetitive V2 receptor antagonist
AU2020278977B2 (en) GPCR heteromer inhibitors and uses thereof
Yamada et al. In vitro and ex vivo effects of a selective nociceptin/orphanin FQ (N/OFQ) peptide receptor antagonist, CompB, on specific binding of [3H] N/OFQ and [35S] GTPγS in rat brain and spinal cord
Jewell et al. Control of CaV2 calcium channels and neurosecretion by heterotrimeric G protein coupled receptors
White et al. CXCL17 is an endogenous inhibitor of CXCR4 via a novel mechanism of action
Yuliantie et al. Isoquinoline small molecule ligands are agonists and probe-dependent allosteric modulators of the glucagon subfamily of GPCRs
WO2007114925A2 (en) Two pore channels as a therapeutic target to protect against myocardial ischemia and as an adjuvant in cardiac surgery
Choi Regulation of the cell surface expression of voltage-gated potassium channels
Compeer On the molecular pharmacology of EndothelinA receptors: or how EndothelinA agonists can make a difference
Parker et al. Non-specific binding and general cross-reactivity of Y receptor agonists are correlated and should importantly depend on their acidic sectors